- Home
- / AgeX Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
AgeX Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$11.1
2024-03-26
Market Capitalization
$27.8 M
2024-03-26
Revenue
$130 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4M | 1.7M | 1.9M | 144.0K | 34.0K | 142.0K | 56.0K | 130.0K |
| Cost of goods sold | 364.0K | 244.0K | 158.0K | 19.0K | 13.0K | 40.0K | ||
| Gross profit | 1.0M | 1.5M | 1.7M | 125.0K | 21.0K | 102.0K | ||
| Gross profit margin, % | 73.9% | 85.9% | 91.5% | 61.8% | ||||
| General and administrative expense | 8.1M | 7.4M | 6.7M | 6.0M | 9.3M | 9.6M | 11.0M | |
| Operating expense total | 12.3M | 14.0M | 12.4M | 8.1M | 7.0M | 10.0M | 17.1M | 24.2M |
| EBIT | (11.2M) | (12.6M) | (10.7M) | (7.9M) | (7.0M) | (9.9M) | (17.0M) | (24.0M) |
| EBIT margin, % | -805.5% | -726.8% | -571.3% | -20514.7% | -30442.9% | -18478.5% | ||
| Interest income | 183.0K | 294.0K | ||||||
| Interest expense | 116.0K | 29.0K | 499.0K | (1.1M) | 4.9M | 17.0K | ||
| Pre tax profit | (12.2M) | (11.1M) | (8.7M) | 10.5M | 14.8M | (11.1M) | (19.2M) | |
| Income tax expense | 148.0K | (150.0K) | 18.0K | |||||
| Net Income | (7.7M) | (12.4M) | (11.0M) | (8.7M) | (10.5M) | (14.8M) | (11.2M) | (19.2M) |
| EPS | (13.0) | (1.5) | (1.9) |